紫杉醇涂层器械在外周动脉疾病中的死亡率分析
该研究为多中心随机开放标签注册临床试验的中期分析,纳入2289例外周动脉疾病患者,比较紫杉醇涂层器械与未涂层器械的全因死亡率。平均随访2.49年,两组死亡率无显著差异(HR 1.06,95%CI 0.92-1.22),在慢性肢体威胁性缺血和间歇性跛行亚组中亦无差异。
要点
- 紫杉醇涂层器械与未涂层器械的全因死亡率无显著差异(HR 1.06,95%CI 0.92-1.22)。
- 慢性肢体威胁性缺血患者中两组死亡率分别为33.4%和33.1%,无显著差异。
- 间歇性跛行患者中两组死亡率分别为10.9%和9.4%,无显著差异。
核心结论
- 在1至4年随访期间,紫杉醇涂层器械与未涂层器械的全因死亡率无显著差异。
研究设计与样本
- 多中心、随机、开放标签、注册为基础的临床试验的中期分析。
- 共2289例患者随机分配至药物涂层器械组(1149例)或未涂层器械组(1140例)。
- 随机化按疾病严重程度分层:慢性肢体威胁性缺血1480例,间歇性跛行809例。
主要发现
- 平均随访2.49年,共574例死亡,药物涂层器械组293例(25.5%),未涂层器械组281例(24.6%),风险比1.06(95%CI 0.92-1.22)。
- 1年时全因死亡率药物涂层器械组为10.2%(117例),未涂层器械组为9.9%(113例)。
- 慢性肢体威胁性缺血患者中,药物涂层器械组死亡率33.4%(249例),未涂层器械组33.1%(243例),无显著差异。
- 间歇性跛行患者中,药物涂层器械组死亡率10.9%(44例),未涂层器械组9.4%(38例),无显著差异。
临床怎么用
- 对于外周动脉疾病患者,使用紫杉醇涂层器械未显示增加全因死亡风险。
局限性
- 该分析为未计划的中期分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The results of a recent meta-analysis aroused concern about an increased risk of death associated with the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular interventions for symptomatic peripheral artery disease. METHODS: We conducted an unplanned interim analysis of data from a multicenter, randomized, open-label, registry-based clinical trial. At the time of the analysis, 2289 patients had been randomly assigned to treatment with drug-coated devices (the drug-coated-device group, 1149 patients) or treatment with uncoated devices (the uncoated-device group, 1140 patients). Randomization was stratified according to disease severity on the basis of whether patients had chronic limb-threatening ischemia (1480 patients) or intermittent claudication (809 patients). The single end point for this interim analysis was all-cause mortality. RESULTS: No patients were lost to follow-up. Paclitaxel was used as the coating agent for all the drug-coated devices. During a mean follow-up of 2.49 years, 574 patients died, including 293 patients (25.5%) in the drug-coated-device group and 281 patients (24.6%) in the uncoated-device group (hazard ratio, 1.06; 95% confidence interval, 0.92 to 1.22). At 1 year, all-cause mortality was 10.2% (117 patients) in the drug-coated-device group and 9.9% (113 patients) in the uncoated-device group. During the entire follow-up period, there was no significant difference in the incidence of death between the treatment groups among patients with chronic limb-threatening ischemia (33.4% [249 patients] in the drug-coated-device group and 33.1% [243 patients] in the uncoated-device group) or among those with intermittent claudication (10.9% [44 patients] and 9.4% [38 patients], respectively). CONCLUSIONS: In this randomized trial in which patients with peripheral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices, the results of an unplanned interim analysis of all-cause mortality did not show a difference between the groups in the incidence of death during 1 to 4 years of follow-up. (Funded by the Swedish Research Council and others; ClinicalTrials.gov number, NCT02051088.).
引用
- Nordanstig J, James S, Andersson M, et al. Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease. N Engl J Med. 2020. PMID: 33296560. doi:10.1056/NEJMoa2005206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。